Thursday, September 1, 2022 Daily Archives

Case Study – Merck Process Transfer and Scale-Up of Batch Chromatography to Multi-Column Platform

by

Traditional batch chromatography has high operating costs. Merck sought to evaluate the relative performance and costs of an MCC system. Learn how Merck achieved resin savings and productivity gains by implementing multi-column chromatography with the Sartorius BioSMB System. Key Learning Objectives: Learn how Merck achieved 3.5x higher productivity with MCC compared to batch mode See how the shift resulted in 80% reduction in chromatographic resin use Find out how Sartorius experts supported Merck’s process transfer Access this case study and…

September 1, 2022

BioProcess Insider Interview: Dr. Ger Brophy, Avantor

by

Moderator: Dan Stanton, Co-founder and Editor, BioProcess Insider. Featuring: Dr. Ger Brophy, Executive Vice President, Biopharma Production, Avantor. Avantor has expanded its biopharmaceutical capabilities significantly over the past year. In addition to opening facilities in The Netherlands and Massachusetts for manufacturing and distribution of single-use systems, respectively, the company has broken ground on sites in Ireland and Singapore. Avantor also acquired Masterflex, a manufacturer of peristaltic pumps and fluid-handling solutions. Brophy explained that such activity exemplifies Avantor’s efforts to increase…

September 1, 2022

LuinaBio: Ampersand adds another CMDO to portfolio

by

Biotech investor Glenn Haifer and private equity firm Ampersand Capital Partners have acquired microbial CDMO LuinaBio and renamed it AcuraBio. LuinaBio has been a microbial contract development and manufacturing organization (CDMO) for over 20 years but will now be rebranded as AcuraBio following the acquisition. No financials have been disclosed but the new owners, Haifer and Ampersand, plan to increase the contract development and manufacturing organization’s (CDMO) production facility capacity, located near Brisbane, Australia. “We are very excited to be…

September 1, 2022

ElevateBio inks deal with Pittsburgh University to accelerate CGTs

by

ElevateBio will use its development and manufacturing platform, BaseCamp, to support the University of Pittsburgh’s cell and gene therapy (CGT) pipeline. The long-term partnership between ElevateBio and the University of Pittsburgh aims to develop CGTs through the implementation of viral vector and cell therapy process development and manufacturing platform, BaseCamp. BaseCamp is designed for both commercial and clinical cell and gene therapies as well as regenerative medicines.  And according to ElevateBio, the University of Pittsburgh will be fully equipped with…

September 1, 2022